Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10852072 | 1.00 | HCAR2 (0.66) | HCAR2ATMFAAHAPPMAPT | |
| SCHEMBL9592279 | 1.00 | HCAR2 (0.66) | HCAR2ATMFAAHAPPMAPT | |
| SCHEMBL1572962 | 1.00 | HCAR2 (0.66) | HCAR2ATMFAAHAPPMAPT | |
| SCHEMBL15365962 | 1.00 | HCAR2 (0.66) | HCAR2ATMFAAHAPPMAPT | |
| SCHEMBL15365968 | 1.00 | HCAR2 (0.66) | HCAR2ATMFAAHAPPMAPT | |
| SCHEMBL1852690 | 1.00 | HCAR2 (0.66) | HCAR2ATMFAAHAPPMAPT | |
| SCHEMBL10857755 | 1.00 | HCAR2 (0.66) | HCAR2ATMFAAHAPPMAPT | |
| SCHEMBL15366125 | 1.00 | HCAR2 (0.66) | HCAR2ATMFAAHAPPMAPT | |
| SCHEMBL8032532 | 1.00 | HCAR2 (0.66) | HCAR2ATMFAAHAPPMAPT | |
| SCHEMBL502571 | 1.00 | HCAR2 (0.66) | HCAR2ATMFAAHAPPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457567-B1 | Agent having neurotrophic factor-like activity | NAGOYA IND SCIENCE RES INST (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-2695613-A1 | ANALGESIC | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2014-02-12 | — | — | EP | disclosed |
| EP-2671578-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR PERIPHERAL NEUROPATHY CAUSED BY ANTICANCER AGENT | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-20130296425-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR A PERIPHERAL NERVE DISORDER INDUCED BY ANTI-CANCER AGENTS | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296426-A1 | ANALGESIC | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2457567-A1 | Agent having neurotrophic factor-like activity | Nagoya Industrial Science Research Institute (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20100204498-A1 | AGENT HAVING NEUROTROPHIC FACTOR-LIKE ACTIVITY | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2010-08-12 | — | — | US | disclosed |
| EP-2204172-A1 | AGENT HAVING NEUROTROPHIC FACTOR-LIKE ACTIVITY | Nagoya Industrial Science Research Institute (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-4132750-A | RING OPENING POLYMERIZATION OF NORBORNENE DERIVATIVES | SHOWA DENKO K.K. (JP) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296425-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR A PERIPHERAL NERVE DISORDER INDUCED BY ANTI-CANCER AGENTS | ALOX5, CPT1B, PMP22 | HCAR2 275/4885ATM 4591/4885FAAH 26/4885 |
| US-20130296426-A1 | ANALGESIC | CNTN1, SHARPIN, HCAR2 | HCAR2 3/4885ATM 4872/4885FAAH 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.